missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human KCTD3 (aa 102-223) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (90%), Rat (90%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-53287 (PA5-53287. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
This gene encodes a member of the potassium channel tetramerization-domain containing (KCTD) protein family. Members of this protein family regulate the biophysical characteristics of ion channels. In mouse, this protein interacts with hyperpolarization-activated cyclic nucleotide-gated channel complex 3 and enhances its cell surface expression and current density. Alternative splicing results in multiple transcript variants.
Specifications
Specifications
| Accession Number | Q9Y597 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 51133 |
| Name | Human KCTD3 (aa 102-223) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 4930438A20Rik; 9330185B06; BTB/POZ domain-containing protein KCTD3; E330032J19Rik; Kctd3; LOW QUALITY PROTEIN: BTB/POZ domain-containing protein KCTD3; NY-REN-45; NY-REN-45 antigen; potassium channel tetramerisation domain containing 3; potassium channel tetramerization domain containing 3; Ren-45; renal carcinoma antigen NY-REN-45; si:dkey-46n18.2 |
| Common Name | KCTD3 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction